Navigation Links
Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
Date:3/23/2010

IRVING, Texas, March 23 /PRNewswire/ -- Usability Sciences Corporation launches its WebIQ Pharma offering, an intelligent survey solution that provides pharmaceutical sites with metrics to answer critical questions about site and content effectiveness, to increase return on investment (ROI).  Usability Sciences has provided usability and user experience research to Merck (MRK), Eli Lilly (LLY), Novartis (NVS) and Ortho McNeil for over ten years.

Pharmaceutical brands build websites primarily to drive drug adoption. The brands want site visitors who have never tried the drug to make appointments with their doctors to discuss the drug. The brands want visitors who have been prescribed the drug to keep taking it and get their prescriptions refilled. Most importantly, the brands need to know which content areas drive the desired behaviors and which content areas do not.  Establishing the link between visitor response to the site and the content that determined their response has heretofore been extremely difficult. WebIQ Pharma makes it simple and, compared to the labor-intensive alternatives, extremely cost effective.

"WebIQ Pharma employs intelligent survey technology and intelligent dashboards in delivering this patented solution," said Usability Sciences President Jeff Schueler. "The intelligent survey technology allows the brand to ask questions of site visitors based on where they went on the site and what content they saw. WebIQ Pharma dashboards, rather than deliver more 'dumb' data, provide answers to the site's key business questions."

Usability Sciences developed the methodology specifically for the pharmaceutical industry, where brand sites often carry high costs but generate relatively low traffic. WebIQ Pharma arms the brand with a continuous stream of answers to drug adoption questions and allows them to constantly improve site stickiness, conversion, and ROI. WebIQ Pharma is flexible and can be customized to fit any brand's needs and preferences in terms of options and pricing.

More information can be found at www.usabilitysciences.com/solutions/webiq/webiq-pharma or by contacting the company directly at info@usabilitysciences.com.

About Usability Sciences:

With more than 20 years of experience in the usability and user experience arena, Usability Sciences has developed an industry-leading portfolio of research methodologies that delivers robust and actionable results to its Fortune 500 client base. For more information about Usability Sciences' service offerings, go to www.usabilitysciences.com or call 1-800-820-1222.

    
    
    Press Release Contact Information:
    Jeff Schueler
    Media Liaison
    Usability Sciences Corporation
    (972) 550-1599
    jschueler@usabilitysciences.com

This release was issued through WebWire(R). For more information visit http://www.webwire.com.

SOURCE Usability Sciences Corporation

Back to top

RELATED LINKS
http://www.usabilitysciences.com

'/>"/>

SOURCE Usability Sciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
8. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
Breaking Medicine News(10 mins):